TICKERNERD
Menu
YARWYARWHealthcare · Biotechnology

YARW Stock Forecast: Yarrow Bioscience, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$29
−4.22% on the day

The 3 Wall Street analysts covering Yarrow Bioscience, Inc. hold a median 12-month price target of $57 — +94.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 19 Sept 2026 — in the upper half.

Market cap
$78.2M
Ticker Nerd rank
56 / 100
Median analyst target
$57
Analysts covering
3
Revenue$97K+40.6% y/y
Operating income−$3.1M
Net income−$3.0M
Free cash flow$67.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+8.4%
1M
−29.5%
YTD
+45.0%
1Y
+171.4%
From 52W high
−31.8%
From 52W low
+176.7%
$11
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

YARW stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Yarrow Bioscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
56 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
78
Accruals
74
Size
65
Value
57
Momentum
53
Quality
47
Revisions
41
Volatility
40
Issuance
29

Growth (78): Sales and profits are climbing, and climbing faster than before.

Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

YARW stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on YARW, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26YARWHigh $58Median $57Low $56

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $56Median $57High $58

The green dot is the last close — the median target sits +94.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2026BTIGInitiatesBuy$58
28 July 2026TD CowenInitiatesBuy—
30 July 2025HC Wainwright & Co.DowngradeNeutral—
25 Apr 2025HC Wainwright & Co.MaintainsBuy—
6 Mar 2025HC Wainwright & Co.ReiteratesBuy—
19 Feb 2025HC Wainwright & Co.ReiteratesBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—
6 Jan 2025HC Wainwright & Co.ReiteratesBuy—
23 Dec 2024HC Wainwright & Co.ReiteratesBuy—
18 Nov 2024BTIGInitiatesBuy—
8 Nov 2024HC Wainwright & Co.ReiteratesBuy—
12 Sept 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
14 June 2024HC Wainwright & Co.ReiteratesBuy—
5 June 2024HC Wainwright & Co.ReiteratesBuy—
9 May 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024HC Wainwright & Co.ReiteratesBuy—
29 Feb 2024HC Wainwright & Co.ReiteratesBuy—
30 Oct 2023HC Wainwright & Co.MaintainsBuy—
14 Aug 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. YARW appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

YARW vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Yarrow Bioscience, Inc. returned +171.4% against +16.3% for the S&P 500, dividends included.

YARW vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Oct 25Jan 26Apr 26Jul 26YARWS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

YARW analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Yarrow Bioscience, Inc. (YARW) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.7×

Cheaper than 71% of US stocks

Price / sales
42.0×

Cheaper than 6% of US stocks

Price / book
0.0×

Cheaper than 92% of US stocks

EV / EBITDA
0.2×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
−57.4%

Higher than 5% of US stocks

Earnings growth (YoY)
−57.4%

Higher than 9% of US stocks

Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−63.2%

Higher than 18% of US stocks

Return on assets
−37.0%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Yarrow Bioscience, Inc. (YARW) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Yarrow Bioscience, Inc. has a market value of $78.2M and an enterprise value of $170.4M.

  • Revenue in the twelve months to 30 June 2026: $266K. The latest quarter shrank 57.4% year on year.

  • Net income over the same four quarters: −$84.0M, a −31588.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−4,472.81.

  • Free cash flow in the twelve months to 30 June 2026: −$13.0M.

  • Shares outstanding: 2.8M.

  • Trailing P/E: 0.7×; forward P/E: −17.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Yarrow Bioscience, Inc. employs 7 people — $38K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

YARW vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
YARWYarrow Bioscience, Inc.$78.2M
56
STROSutro Biopharma, Inc.$251.4M
72
FHTXFoghorn Therapeutics, Inc.$242.5M
69
PRQRProQR Therapeutics NV$252.7M
44
WHWKWhitehawk Therapeutics, Inc.$239.4M
73
LCTXLineage Cell Therapeutics, Inc.$256.6M
53
CGENCompugen Ltd.$235.4M
81

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Yarrow Bioscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest YARW news & analysis

Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Business Wire · 14 Sept 2026neutral

Yarrow Bioscience announced the closing of its underwritten public offering of 6,634,615 shares of common stock at $26.00 per share, including the full exercise of the underwriters' option for 865,384 additional shares, for total gross proceeds of $172.5 million.

Why it matters — The completion of the offering gives Yarrow fresh capital to fund its pipeline of therapies for autoimmune thyroid diseases, which is material to the company's near-term runway.

Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering

Business Wire · 11 Sept 2026neutral

Yarrow Bioscience, Inc. announced the pricing of its underwritten public offering of 5,769,231 shares of common stock at $26.00 per share, with expected aggregate gross proceeds of approximately $150 million.

Why it matters — This capital raise provides Yarrow with approximately $150 million in gross proceeds to fund its clinical-stage development programs for autoimmune thyroid disease therapies.

Yarrow Bioscience Announces Proposed Underwritten Public Offering

Business Wire · 10 Sept 2026neutral

Yarrow Bioscience announced that it has commenced an underwritten public offering of shares of its common stock, or pre-funded warrants to purchase common stock for certain investors. The company also expects to grant the underwriter related warrants.

Why it matters — A Yarrow watcher would care because the offering could affect the company's share count and capital position.

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease

Business Wire · 27 July 2026positive

Yarrow Bioscience announced the completion of its merger with VYNE Therapeutics and the initiation of dosing in a Phase 2a/2b trial of YB-101 for Graves' disease and thyroid eye disease, along with private financings totaling approximately $200 million.

Why it matters — VYNE watchers would care because the company has been merged into Yarrow Bioscience, which now has a funded clinical program underway for a potential first-in-class treatment for autoimmune thyroid diseases.

FAQ

Frequently asked questions about YARW stock

What is the YARW stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Yarrow Bioscience, Inc. have a median 12-month price target of $57, with estimates ranging from $56 to $58. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is YARW stock a buy right now?

Of the 3 analysts covering Yarrow Bioscience, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Yarrow Bioscience, Inc. 56 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank YARW?

As at 19 Sept 2026, Yarrow Bioscience, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (78 of 100).

Will YARW stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +94.6% from the last close, and Ticker Nerd's factor model ranks Yarrow Bioscience, Inc. 56 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the YARW stock forecast for 2030?

No analyst covering Yarrow Bioscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for YARW are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $56 to $58 over the next 12 months.

How has YARW stock performed over the past year?

Yarrow Bioscience, Inc. returned +171.4% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Yarrow Bioscience, Inc. do?

Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune thyroid diseases.

What is the latest news on YARW?

The most recent item we track (Business Wire, 14 Sept 2026): "Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares". Yarrow Bioscience announced the closing of its underwritten public offering of 6,634,615 shares of common stock at $26.00 per share, including the full exercise of the underwriters' option for 865,384 additional shares, for total gross proceeds of $172.5 million.

Company

About Yarrow Bioscience, Inc.

Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune thyroid diseases. Its lead product candidate, YB-101, is a humanized monoclonal antibody designed to target the thyroid-stimulating hormone receptor for conditions such as Graves’ disease and thyroid eye disease. The company concentrates on research and development programs centered on these disorders, aiming to address the underlying disease mechanism rather than only managing symptoms. Yarrow Bioscience participates in the biotechnology and pharmaceutical research market, where it advances biologic drug candidates intended for specialized endocrine and immunology indications. The company is headquartered in New Haven, Connecticut, and operates as a focused drug-development platform with a current emphasis on its thyroid autoimmunity pipeline.

CEO Ms. Rebecca Velez Frey Pharm.D. · 7 employees · United States · https://www.yarrowbioscience.com